A 24-week, open-label extension study to investigate the long-term safety, tolerability, and efficacy of 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 29, Issue 2, 2015, Pages 110-116

  Farlow, Martin R ^a   Grossberg, George T ^b   Sadowsky, Carl H ^c   Meng, Xiangyi ^d   Velting, Drew M ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVA SOUTHEASTERN UNIVERSITY   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

open label clinical trial; rivastigmine; severe Alzheimer disease; transdermal patch

Indexed keywords

RIVASTIGMINE; CHOLINESTERASE INHIBITOR;

ABNORMAL LABORATORY RESULT; AGED; AGITATION; ALZHEIMER DISEASE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING SCALE CLINICAL GLOBAL IMPRESSION OF CHANGE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING SCALE SERVERE IMPAIRMENT VERSION; APPLICATION SITE DERMATITIS; APPLICATION SITE ERYTHEMA; ARTICLE; DEMENTIA ASSESSMENT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; SEVERE IMPAIRMENT BATTERY; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; CHEMICALLY INDUCED; DAILY LIFE ACTIVITY; DOSE RESPONSE; LONGITUDINAL STUDY; NEUROPSYCHOLOGICAL TEST; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TRANSDERMAL PATCH; TREATMENT OUTCOME; VERY ELDERLY;

ACCIDENTAL FALLS; ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; RIVASTIGMINE; SEVERITY OF ILLNESS INDEX; TRANSDERMAL PATCH; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; WEIGHT LOSS;

EID: 84930763160     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000073     Document Type: Article

References (25)

1. Alzheimer's Association. Alzheimer's Disease Facts and Figures. 2013. Available at: http://www.alz.org/downloads/facts-figures-2013.pdf. Accessed July 8, 2013.
2. Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with done-pezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol. 2011;11:21.
3. s (donepezil hydrochloride) tablets prescribing Information. 2013. Available at: http://labeling.pfizer.com/ShowLabeling. aspx?id= 510. Accessed July 9, 2014.
4. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA: Exelon capsules prescribing Information. 2008. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/020823s016, 021025s008lbl.pdf. Acessed July 9, 2014.
5. s (rivastigmine tartrate) prescribing Information. 2013. Available at: http://www.pharma.us.novartis. com/product/pi/pdf/exelonpatch.pdf. Accessed July 9, 2014.
6. s (galantamine hydrobromide) tablets and oral solution prescribing information. 2013. Available at: http://www.razadyneer.com/sites/default/files/shared/pi/razadyne-er. pdf. Accessed July 9, 2014.
7. Forest Pharmaceuticals Inc., St Louis, MO, USA: Namenda XRt (memantine hydrochloride) tablets and oral solution [Prescribing Information]. 2013. Available at: http://www.frx.com/pi/namenda-pi.pdf. Accessed July 9, 2014.
8. 2) in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33:341-353.
9. Farlow M, Grossberg G, Sadowsky C, et al. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther. 2013;19:245-252.
10. Farlow M, Grossberg G, Gauthier S, et al. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Curr Med Res Opin. 2010;26:2441-2447.
11. Farlow M, Grossberg G, Sadowsky C, et al. A 24-week, open-label extension to the ACTivities of daily living and cognitION (ACTION) study: Long-term safety, tolerability and efficacy of a 13.3 mg/24h rivastigmine patch in people with severe Alzheimer's disease. Alzheimers Dement. 2013;9:655, P3-270.
12. Farlow M, Grossberg G, Sadowsky C, et al. Long-term safety, tolerability and efficacy of 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease. American College of Clinical Pharmacology Annual Meeting September 22nd-24th Bethesda, Maryland. Clin Pharm Drug Dev. 2013;2:P3-20.
13. Farlow MR, Grossberg G, Sadowsky C, et al. Long-term safety and efficacy of 13.3 mg/24h rivastigmine patch in severe Alzheimer's disease: ACTivities of daily living and cognitION (ACTION) study. J Neurol Sci. 2013;333:e339, 115.
14. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
16. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39.
17. Saxton J, McGonigle-Gibson K, Swihart A, et al. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess. 1990;2:298-303.
18. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S22-S32.
19. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs. 2001;15:375-390.
20. Grossberg G, Sadowsky C, Forstl H, et al. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord. 2009;23:158-164.
21. Teri L, McCurry SM, Edland SD, et al. Cognitive decline in Alzheimer's disease: a longitudinal investigation of risk factors for accelerated decline. J Gerontol A Biol Sci Med Sci. 1995;50A:M49-M55.
22. Blesa R, Ballard C, Orgogozo JM, et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology. 2007;69:S23-S28.
23. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22:485-491.
24. Boada M, Arranz FJ. Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine. Dement Geriatr Cogn Disord. 2013;35:23-33.
25. Ale I, Lachapelle JM, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther. 2009;26:920-935.